Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan

CDT Equity Inc.

Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.
Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.
Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.
All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified.

item 5.02item 5.03item 5.07item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.